Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec to Present at the Cowen and Company 37th Annual Health Care Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated
View HTML
Toggle Summary Oxford Immunotec Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec to Present at the Leerink Partners 6th Annual Global Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated
View HTML
Toggle Summary Oxford Immunotec to Present at the 35th Annual J.P. Morgan Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated
View HTML
Toggle Summary Oxford Immunotec Announces New England Journal of Medicine Publication on Clinical Trial Results of Serological and Nucleic Acid Tests for Babesia in Blood Screening
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec to Present at the 28th Annual Piper Jaffray Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Ranked Among Deloitte's 2016 Technology Fast 500™
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions today
View HTML
Toggle Summary Oxford Immunotec to Present at the Jefferies 2016 London Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Reports Third Quarter 2016 Financial Results
Third quarter revenue of $26.1 million, an increase of 46% compared to prior year period Tuberculosis revenue of $22.0 million, an increase of 23% compared to prior year period Tick-borne disease and other revenue of $4.1 million Completed acquisitions of Imugen and Immunetics expanding offerings
View HTML
Toggle Summary Oxford Immunotec Schedules Third Quarter 2016 Earnings Release and Conference Call for November 1, 2016
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated
View HTML